Early Pre-Pilot Study Advances Potassium Biosensor
Open PDF
| Stock | Archer Materials Ltd (AXE.ASX) |
|---|---|
| Release Time | 13 Aug 2026, 9:27 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Archer Materials Advances Potassium Biosensor Development
Key Points
- Early pre-pilot study involving 20 donors completed.
- Capillary blood collection approach identified with low haemolysis.
- Findings to inform beta prototype engineering and future studies.
Full Summary
Archer Materials Limited announced results from an early-stage blood collection study, a critical step in developing its potassium Biosensor. The study, involving 20 donors, evaluated capillary and conventional venous blood collection methods, finding a capillary approach with haemolysis levels comparable to venous collection. These findings will guide Archer in refining its blood sample collection and processing workflow, crucial for accurate potassium measurement. The study's outcomes are expected to support future pilot and pivotal studies and regulatory engagement, including a planned FDA Pre-Submission.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In